

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Racura Oncology Limited
ABN	61 149 318 749

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Daniel Tillett
Date of last notice	19 February 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	2 April 2026
No. of securities held prior to change	18,621,009 fully paid ordinary shares 1,648,342 options exercisable at \$1.25, expiring 29/5/2026 1,534,712 options exercisable at \$1.45, expiring 29/11/2028 3,061,101 options exercisable at \$4.25, expiring 29/11/2028 432,680 options exercisable at \$1.67, expiring 30/6/2029
Class	Fully paid ordinary shares Options exercisable at \$1.25, expiring 29/5/2026
Number acquired	200,000 fully paid ordinary shares
Number disposed	200,000 options exercisable at \$1.25, expiring 29/5/2026

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$250,000
No. of securities held after change	18,821,009 fully paid ordinary shares 1,448,342 options exercisable at \$1.25, expiring 29/5/2026 1,534,712 options exercisable at \$1.45, expiring 29/11/2028 3,061,101 options exercisable at \$4.25, expiring 29/11/2028 432,680 options exercisable at \$1.67, expiring 30/6/2029
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Exercise of 200,000 options exercisable at \$1.25, expiring 29/5/2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only